ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancerRowan Miller, Lucy Yates, Alexandra Léary et al.|Annals of Oncology|2020Cited by 478
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 studyÉric Pujade-Lauraine, Bradley J. Monk, Kyung Hae Jung et al.|The Lancet Oncology|2021Cited by 401
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAntonio González-Martı́n, Jonathan A. Ledermann, Philipp Harter et al.|Annals of Oncology|2023Cited by 381
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent diseaseJonathan A. Ledermann, Anna Fagotti, Xavier Matías‐Guiu et al.|Annals of Oncology|2024Cited by 277
517O Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trialPaul DiSilvestro, K.N. Moore, Susana Banerjee et al.|Annals of Oncology|2022Cited by 6